VCP Scanner
ScreenerTechnicalBreakoutsThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistPricing
ScreenerTechnical ScannerBreakoutsThemes
Earnings
WatchlistPricing
Ctrl K
TMO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
TMOThermo Fisher Scientific Inc.
$588.29$218.6B
Overview & Verdict
OverviewAnalysisVisualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksTMOAnalysis
TMO logo

Thermo Fisher Scientific Inc. (TMO) Research Brief

Wall Street consensus, price target range, and equity research thesis

Buy43 Analyst Coverage
Consensus Target
$598+1.6% Upside
Current: $588.29
Analyst Range
Low $520High $650
12-Month High/Low Spread
Ratings Mix
36 Buy·7 Hold·0 Sell
Earnings & Valuation
EPS Beat 5.4%
Forward P/E: 23.5x

Executive Summary & Research Take

Wall Street currently rates TMO buy with a 12-month price target of $598 (+1.6% upside). The sections below cover the bull case, key risks, and latest earnings context for Thermo Fisher Scientific Inc..

Recent Analyst Actions

TMO Analyst Upgrades & Price Target Changes

1 raised, 1 cut of 2 analysts. Recent price target changes and ratings for TMO.

Updated Jun 2026
FirmActionRatingPrice Target
Piper SandlerInitiatedNeutral$510
HSBCCutHold$670$540

Analyst ratings update weekly. Get TMO's next verdict in your inbox.

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

Analyst Research Summary

Investment Thesis: Bull Case & Risk Factors

A structured look at the bull case, the risks, and the most recent earnings execution for TMO.

Current setup

TMO beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.

Bull Case

What keeps the long thesis intact

  • 5G Market LeadershipT-Mobile holds approximately 35% of the wireless market share and its Ultra Capacity 5G network reaches nearly 98% of the U.S. population.
  • Strong Revenue GrowthQ1 2026 revenues reached $23.11 billion, marking an 11% year-over-year increase, with EPS at $2.27, exceeding forecasts.
  • Significant Capital ReturnsThe company expects to return up to $18.2 billion to stockholders in 2026 through share repurchases and dividends.
  • Broadband Expansion GoalsT-Mobile aims to reach 18-19 million total broadband customers by 2030 through its Fixed Wireless Access and fiber partnerships.
  • Successful Integration of U.S. CellularThe integration of U.S. Cellular is progressing well and is expected to complete by the end of 2026, enhancing market presence.
  • Positive Analyst SentimentAnalysts generally hold a positive view, with a consensus rating of 'Buy' and a median price target around $261.00.

Wall Street rates TMO buy, giving the bull case institutional backing from 43 analysts.

Watch Out For

What can break the setup quickly

  • Intense Industry CompetitionRivals like Verizon and AT&T are heavily investing in their networks, which could pressure T-Mobile's market share and pricing.
  • Concerns Over Subscriber GrowthThere are worries about slowing postpaid phone net adds and potential increases in churn rates, particularly in smaller markets.
  • High Debt LevelsT-Mobile carries a significant debt load of $86.95 billion as of December 2025, increasing financial risk in a rising interest rate environment.
  • Valuation ConcernsSome analysts note T-Mobile's higher P/E ratio compared to the industry average, raising concerns about valuation amidst rising operational costs.
  • Regulatory RisksThe telecommunications sector faces regulatory scrutiny, and macroeconomic factors could impact capital spending and consumer behavior.
  • Limited Broadband OfferingT-Mobile's current broadband offerings may be limited compared to competitors in the bundled fiber/mobility market.

Watch whether new negative commentary on TMO points to these structural risks or is simply reacting to short-term price moves.

TMO Earnings Reaction — What the Last Quarter Showed

Last Quarter

EPS
$6.03 vs $5.72 est.Beat 5.4%
Revenue
$12.0B vs $11.7B est.Beat 2.5%
Consensus-Based Analysis Tools

TMO Stock Overview

Stock snapshot, live price chart, key ratios, and company profile.

View Overview

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

TMO — Frequently Asked Questions

Quick answers to the most common questions about buying TMO stock.

What is the analyst consensus on TMO?
Verdict

TMO appears fairly valued near today's $588.29 — the consensus rating is "Buy" with a $598 target (+1.6%). This is informational only — verify the data and consider your own risk tolerance before deciding.

What are recent analyst rating changes for TMO?
Timing

Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +1.6% upside to the $598 target. Recent activity is mixed — 1 analysts raised and 1 cut targets in the past 30 days.

What is the price target for TMO stock?
Price Target

TMO's consensus 12-month price target is $598, set by 43 Wall Street analysts. The bull case high is $650 and the bear case low is $520. From the current price of $588.29, this implies +1.6% upside.

Is TMO overvalued or undervalued?
Valuation

TMO appears fairly valued — the $598 consensus target is roughly in line with today's $588.29 (+1.6%). It trades at a forward P/E of 23.5x. Targets range from $520 (bear) to $650 (bull), reflecting different assumptions about growth and margins.

What were TMO's latest earnings results?
Earnings

TMO reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $598 target. Consider position sizing rather than going all-in pre-print.

What is the bull case for TMO?
Coverage

Of 43 analysts covering Thermo Fisher Scientific Inc. (TMO): 0 Strong Buy, 36 Buy, 7 Hold, 0 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $598 (range $520–$650). Bullish analysts outnumber bearish by more than 2-to-1.

What are the risks of investing in TMO?
Risks

No analyst currently rates TMO a Sell, but the 7 Hold ratings reflect concerns about valuation, execution risk, or near-term catalysts. See the Bull vs. Risk cards above for the specific theses on Thermo Fisher Scientific Inc..

Financial Data & Software Notice: VCP Scanner is an educational financial research database and stock screening software platform. VCP Scanner does not generate, recommend, or package trade decisions, buy/sell signals, or personalized investment advice. Consensus ratings and price targets reflect aggregated third-party Wall Street analyst research from public SEC filings. See our Terms of Service and Privacy Policy.